A Phase 3 interventional study of AHB-137 and Placebo in Chronic Hepatitis B, sponsored by Ausper Biopharma Co., Ltd.. Active, not recruiting at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Ausper Biopharma Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic — 6 open to participants now, 8 under way, 1 of them phase 3. Hepatitis B Virus Antisense Oligonucleotide AHB-137 · Hepatitis B, Chronic.
Among the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, this one has the largest enrollment, is one of 4 that started in 2025, is the only one in phase 3, and was the 6th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →6 of the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic are open now, in 12 countries. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65
AusperBio Therapeutics Inc. · Sites in Australia, China, Japan and 4 more countries
Ages 18–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 1
First in 2023; this study’s year is marked. 4 started in 2025.
This study's enrollment of 577 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 86 across the 11 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 2 most frequent:
Ausper Biopharma Co., Ltd. is the lead sponsor of 14 studies on the registry; 9 are open to participants now.
13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd.: 8 open now, 11 under way, 1 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd., this one has the largest enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2025, is the only one in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 6th registered.
Ausper Biopharma Co., Ltd.’s Hepatitis B, Chronic studies by the year they started, since 2023.
6 of the studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07246889Phase 3Ausper Biopharma Co., Ltd.Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) | 2026-12-18 |
| NCT07137910Ausper Biopharma Co., Ltd.A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) | 2026-12-12 |
| NCT07654283AusperBio Therapeutics Inc.Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions | 2027-05-11 |
| NCT07635186Ausper Biopharma Co., Ltd.A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B | 2027-06-20 |
| NCT07069569Ausper Biopharma Co., Ltd.A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs | 2027-07-15 |
Add all 6 to your calendar (.ics) → With an account.
Among the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ausper Biopharma Co., Ltd.’s 13 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, multicenter phase 3 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AHB-137 · Drug: NA therapy
Drug: Placebo · Drug: NA therapy
AHB-137 will be injected weekly by subcutaneous injection. There are 2 leading doses on day 4 and day 11.
Placebo will be injected weekly by subcutaneous injection.Two additional doses given on day 4 and day 11.
NA will be the background therapy. After stopping the AHB-137 or placebo injection, continue for another 12 weeks.
Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ) at the 24th week after all treatment for CHB was discontinued
Time frame: 24 weeks after discontinuation of all CHB treatment
Proportion of participants with persistent HBV DNA < LLOQ .
Time frame: 24 weeks after discontinuation of all CHB treatment
Proportion of participants with persistent HBsAg < LOD and HBV DNA < LLOQ
Time frame: Up to 60 weeks
Concentration of HBsAg, HBV DNA, HBV RNA, HBcrAg, HBsAb,HBeAg, HBeAb
Time frame: Up to 60 weeks
Relapse rate after discontinuation of NAs therapy.
Time frame: Up to 60 weeks
Safety: Number and percentage of participants with detectable anti-drug antibodies (ADA).
Time frame: Up to 60 weeks
Safety: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAE) and clinically significant examination results.
Time frame: Up to 60 weeks
Plasma concentrations of AHB-137.
Time frame: Up to 60 weeks
Sequencing of the Viral DNA and/or viral RNA analysis for detection of drug resistance in the target region of AHB-137
Time frame: Up to 60 weeks
Change from baseline in EuroQol Five-Dimension Five-Level Scale (EQ-5D-5L) scores in participants with HBV infection.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Time frame: Up to 60 weeks
Changes of the hepatitis B quality of life (HBQOL) instrument in participants compared with baseline.
This scale has 31 items, including 7 dimensions: psychological status, expected anxiety, vitality, shame, infectivity, health vulnerability, and viral response. Each item is scored on a 5-point scale, with higher scores indicating a more severe impact of hepatitis B on quality of life.
Time frame: Up to 60 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hepatitis B Virus Antisense Oligonucleotide AHB-137